Vedolizumab Trough Levels in Inflammatory Bowel Disease: Initial Clinical Experience

被引：0
|
作者：
Badr, Al-Bawardy [1 ]
Guilherme, Piovezani Ramos [1 ]
Loftus, Edward, Jr. [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2018年 / 113卷
关键词：
D O I：
10.14309/00000434-201802001-00111
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P-111
引用
收藏
页码：S26 / S26
页数：1
相关论文
共 50 条
  • [1] CLINICAL EXPERIENCE WITH VEDOLIZUMAB TROUGH LEVELS IN INFLAMMATORY BOWEL DISEASE
    Al-Bawardy, Badr
    Ramos, Guilherme Piovezani
    Willrich, Maria Alice V.
    Park, Sang Hyoung
    Aniwan, Satimai
    Raffals, Laura H.
    Tremaine, William J.
    Loftus, Edward V.
    [J]. GASTROENTEROLOGY, 2018, 154 (06) : S821 - S822
  • [2] VEDOLIZUMAB TROUGH LEVELS AND ANTIBODIES IN INFLAMMATORY BOWEL DISEASE: UPDATED INITIAL EXPERIENCE
    Al-Bawardy, Badr
    Ramos, Guilherme Piovezani
    Willrich, Maria Alice V.
    Park, Sang
    Raffals, Laura
    Tremaine, William J.
    Loftus, Edward V., Jr.
    [J]. INFLAMMATORY BOWEL DISEASES, 2018, 24 : S62 - S63
  • [3] VEDOLIZUMAB TROUGH LEVELS AND ANTIBODIES IN INFLAMMATORY BOWEL DISEASE: UPDATED INITIAL EXPERIENCE
    Al-Bawardy, Badr
    Ramos, Guilherme Piovezani
    Willrich, Maria Alice V.
    Park, Sang
    Raffals, Laura
    Tremaine, William J.
    Loftus, Edward V., Jr.
    [J]. GASTROENTEROLOGY, 2018, 154 (01) : S89 - S89
  • [4] VEDOLIZUMAB TROUGH LEVELS AND CLINICAL OUTCOMES IN INFLAMMATORY BOWEL DISEASE
    Guidi, L.
    Pugliese, D.
    Tonucci, T. Panici
    Tolusso, B.
    Felice, C.
    Papa, A.
    Ennas, S.
    Di Mario, C.
    Gasbarrini, A.
    Rapaccini, G. L.
    Armuzzi, A.
    [J]. DIGESTIVE AND LIVER DISEASE, 2018, 50 (02) : E99 - E100
  • [5] Clinical utility of vedolizumab trough levels in the management of inflammatory bowel disease
    Maillard, Michel H.
    Jelk, Daniele
    Perreau, Matthieu
    Rossel, Jean-Benoit
    Pittet, Valerie
    Michetti, Pierre
    [J]. SWISS MEDICAL WEEKLY, 2018, 148 : 6S - 6S
  • [6] Vedolizumab trough levels predict clinical outcomes in inflammatory bowel disease
    Guidi, L.
    Pugliese, D.
    Tonucci, T. Panici
    Tolusso, B.
    Felice, C.
    Di Mario, C.
    Papa, A.
    Gremese, E.
    Gasbarrini, A.
    Rapaccini, G. L.
    Armuzzi, A.
    [J]. JOURNAL OF CROHNS & COLITIS, 2018, 12 : S398 - S398
  • [7] CORRELATION OF VEDOLIZUMAB TROUGH LEVELS WITH CLINICAL AND BIOCHEMICAL MARKERS IN INFLAMMATORY BOWEL DISEASE
    Tamilarasan, Aravind Gokul
    Guerrero, Antonio
    Arias, Laura
    Burns, Megan
    Arkir, Zehra
    Irving, Peter
    [J]. GUT, 2019, 68 : A98 - A99
  • [8] Vedolizumab trough levels at Week 6 predict endoscopic and clinical remission in inflammatory bowel disease
    Hanzel, J.
    Sever, N.
    Ferkolj, I.
    Stabuc, B.
    Smrekar, N.
    Kozelj, M.
    Novak, G.
    Gils, A.
    Drobne, D.
    [J]. JOURNAL OF CROHNS & COLITIS, 2018, 12 : S414 - S414
  • [9] VEDOLIZUMAB TROUGH LEVELS AT WEEK 6 PREDICT ENDOSCOPIC AND CLINICAL REMISSION IN INFLAMMATORY BOWEL DISEASE
    Hanzel, Jurij
    Sever, Nejc
    Ferkolj, Ivan
    Stabuc, Borut
    Smrekar, Natasa
    Kozelj, Matic
    Novak, Gregor
    Gils, Ann
    Drobne, David
    [J]. GASTROENTEROLOGY, 2018, 154 (06) : S819 - S819
  • [10] Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease
    Hanzel, Jurij
    Sever, Nejc
    Ferkolj, Ivan
    Stabuc, Borut
    Smrekar, Natasa
    Kurent, Tina
    Kozelj, Matic
    Novak, Gregor
    Compernolle, Griet
    Tops, Sophie
    Gils, Ann
    Drobne, David
    [J]. UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2019, 7 (06) : 741 - 749
12345